Yakult Honsha Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (44)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Yakult Honsha - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Yakult Honsha. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “5” cancer drugs in clinical pipeline and majority of them are in phase-II. There are 3 cancer drugs by Yakult Honsha which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Yakult Honsha - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Yakult Honsha - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Yakult Honsha. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “5” cancer drugs in clinical pipeline and majority of them are in phase-II. There are 3 cancer drugs by Yakult Honsha which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Yakult Honsha - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Yakult Honsha Overview

  1.1 Business Overview

  1.2 Yakult Honsha Cancer Pipeline Overview

 

2. Yakult Honsha Cancer Drugs in Phase-I

  2.1 Soblidotin

 

3. Yakult Honsha Cancer Drugs in Phase-I/II

  3.1 Satraplatin

 

4. Yakult Honsha Cancer Drugs in Phase-II

  4.1 Resminostat

  4.2 Perifosine

 

5. Yakult Honsha Cancer Drugs in Phase-III

  5.1 Doxorubicin Liposomal - Celsion Corporation

 

6. Marketed Cancer Drugs by Yakult Honsha

  6.1 Capecitabine (Xeloda)

  6.2 Oxaliplatin (Dacotin, Dacplat, Eloxatin & Elplat)

  6.3 Irinotecan (Campto, Camptosar, Irkan & Irnocam)

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Acrylonitrile Derivatives - Yakult Honsha

  7.2 Hypoxia-Selective Multi-Kinase Inhibitors - Proacta

  7.3 Biosimilars - API/UMN Pharma/Yakult Honsha

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 LC 9018

  8.2 Bropirimine

  8.3 Adozelesin

  8.4 Lung Cancer Therapeutics - OncoTherapy Science/Yakult Honsha


Figure 1-1: Yakult Honsha Cancer Pipeline by Phase (%)

Figure 1-2: Yakult Honsha Cancer Pipeline by Phase (Number)

Figure 1-3: Yakult Honsha Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Yakult Honsha Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)